In contrast, treatment of MDS-L cells with the HDAC1/HDAC3 inhibitor MS-275 did not alter TET2 levels, although H3K27Ac levels were significantly increased relative to untreated cells (Figure 3E, 3F). Here, HDAC3 is linked to myelodysplastic syndrome.